List view / Grid view
In this Q&A, esteemed Dr Rhoda Alani discusses the epigenetic landscape of therapy resistant melanomas and elucidates how corin treatment impacts the reprogramming of melanoma cell phenotypes. The findings suggest a new treatment paradigm for melanoma which could also be relevant to targeted therapy resistance mechanisms for other cancer types.
A combination therapy of vincristine, irinotecan and panobinostat, tested in high-risk, relapsed or refractory HB spheroids, decreased tumour marker levels.
Many exciting developments are expected to take place in immunotherapy and oncology in the next few years. We had the privilege of discussing the opportunities of various cell therapies with Dr Suresh Nair, Physician in Chief, who elucidates how Lehigh Valley Topper Cancer Institute is directing research towards better treatments,…
New immunotherapies may be developed for patients with HCC associated with steatotic liver disease, with TREM1 suggested as a target.
Tumours with a greater IGR burden could respond better to immune checkpoint blockades, advancing precise treatments for patients.
Using tumour organoids, researchers identified that overexpression of Engrailed-1 blocked genes associated with natural cell death.
Researchers have created dual-targeted CARs, which performed better than single-targeted CARs in both in vivo and in vitro experiments.
Read this in-depth analyses and insights from leading experts in the field focusing on treatments, new technologies and engineered bacteria.
Low-dose positron emission mammography (PEM) has a high sensitivity for detecting cancer and reduces the likelihood of false positives.
Researchers have developed a computational analysis tool which will improve patient stratification and enable personalised medicine.
Disrupting the mechanism that EGFR-driven lung adenocarcinoma uses to alter macrophages’ lipid metabolism could inspire new treatments.
New insights about young-onset CRC tumour-related bacteria could lead to new diagnostic markers and therapeutic targets.
A novel cellular mechanism has been uncovered with the use of CRISPR gene-tiling technology, which could advance oncologic therapies.
Researchers conducted a proteogenomic characterisation and found that drug exposure changes drug sensitivity.
A new study proves that organoid drug testing is highly accurate at predicting effective treatments and finds a novel therapeutic option.
